Intradigm
Intradigm is a private biotechnology company committed to the
discovery, development and delivery of targeted, systemic RNA
interference (RNAi) therapeutics for the treatment of serious diseases
with an initial focus on oncology. Intradigm is unique, among private
companies, with its comprehensive RNAi therapeutics platform consisting
of both proprietary siRNA sequences, and the means to deliver them using
the company's proprietary delivery technology, known as RNAi Nanoplex.
Its RNAi Nanoplex (NPX) delivery technology is unique in its potential
to offer safe and effective systemic administration using a library of
novel peptide-based biodegradable polymers.
The company has recently announced that it has
raised $18.5 million in a Series B financing, led by Lilly Ventures with
participation from other new investors, Roche Venture Fund and MP
Healthcare Venture Management. Existing investors, Frazier Healthcare
Ventures, Alta Partners, MediBic Alliance Technology Fund, and Novartis
Venture Fund also participated in the round. In connection with the
financing, Bryan Dunnivant, principal at Lilly Ventures, will join
Intradigm's board of directors.
